Vaccines against covid-19 are reaching a world that is facing the worst pandemic of the last century: few doses are still being produced, rich countries hoard them to try to return to normality as soon as possible, the agreements with the Pharmaceuticals become ammunition for the political opposition…
But in Germany an unexpected problem has arisen: the rejection of one of the vaccines, that of Oxford and AstraZeneca. In a scenario of generalized shortages, Germany has stored 85% of the immunizations it has received from the Anglo-Swedish company. Out of nearly 1.5 million doses delivered, just over 200,000 have been administered.
The rate of vaccination begins to worry the Government of Angela Merkel and to the experts because these punctures are key to achieving the goal set by the European Union: that 70% of adults are immunized before the end of summer.
London (United Kingdom) .- (FILE) – Pascal Soriot (C), Chief Executive of AstraZeneca, leaves Portcullis House in London, Britain, 14 May 2014 (reissued 27 January 2021). AstraZeneca has rejected EU’s criticism of its vaccine rollout process, after the company had announced delays in delivering the agreed doses to the bloc. (United Kingdom, London) EFE / EPA / FACUNDO ARRIZABALAGA *** Local
News of the alleged decreased effectiveness of the AstraZeneca vaccine has caused thousands of health care workers and other essential workers to miss appointments to receive doses. Germany was the first European country to decide to use this immunization only in people under 65 years of age, due to the lack of data on its effectiveness in the elderly.
That’s when the reputational problem for the AstraZeneca vaccine began to develop, says Hajo Zeeb, an epidemiologist at the Leibniz Institute for Preventive Research and Epidemiology, which has been compounded by “miscommunication” about its effectiveness.
“The AstraZeneca vaccine is safe and very effective. It prevents many infections and protects against serious diseases, ”Merkel’s spokesperson, Steffen Seibert, posted on her Twitter account in response to the dribbling of news in the regional press that recounted how many public employees consider the vaccine worse than the others and prefer to wait. A refusal that in some cases has also been attributed to the supposed worst side effects.
There are already several experts who suggest that it will be necessary to change the vaccination strategy to be able to use the AstraZeneca doses with those who do want to be immunized. Teachers, for example, could be relocated to a higher priority group.
It is an option that the health authorities value, especially since this week they have opened, after two months without face-to-face activity, kindergartens and primary schools in 11 of the 16 German Länder.
The Ministry of Health has confirmed to this newspaper that “since in Germany there is no obligation to be vaccinated against covid-19, there will be people who will receive the vaccination when others reject it.” And a spokesman adds: “But it must be remembered that those who reject it are not protected against the disease.” Germany has vaccinated with the first dose at 3,
“I do not get it. Any vaccine is better than having no protection against the coronavirus, ”says Carsten Watzl, general secretary of the German Immunology Society. “We scientists have to convey the facts to the public: the AstraZeneca vaccine is very good.
The latest study published gives it 80% effectiveness when the doses are spaced between nine and twelve weeks, which is what we are doing in Germany ”, he emphasizes. Watzl also explains that many people have not understood how clinical trials work and what efficacy rates mean.
Just because a vaccine is 80% effective does not mean that a person who gets vaccinated has a 20% chance of getting sick. Vaccines reduce the relative risk, that is, if the risk of becoming seriously ill in a young person is already low without the vaccine,
There is another peculiarity of the AstraZeneca vaccine to take into account. Precisely because it is being administered to those under 65 years of age, more unwanted symptoms are more likely to be reported. “Young people have more side effects than older people,” explains Watzl. The immune system of young people is more active and therefore the reaction to the vaccine is greater.
For this reason, he assures, there is no need to be alarmed when it is published that 20% or 30% of the firefighters or health workers in the same park or hospital have not gone to work the day after the vaccination because they are ill. “It is expected,” he stresses. “The only thing these cases show is the poor planning of those responsible for vaccination,” he adds.
Some federal states are already recommending not administering the vaccine to all employees at the same time to avoid many simultaneous casualties. This is what happened at the Herzogin Elisabeth hospital in Braunschweig, in Lower Saxony, about 150 miles west of Berlin.
On February 11, the center administered 88 doses to as many employees, of whom 37 did not go to work the next day because they were unwell, according to the local newspaper Braunschweiger Zeitung . A spokeswoman for the hospital assured that they were going to temporarily paralyze the campaign so as not to run out of enough staff to care for patients.
A resident of the center, Hristina Markova, told Der Spiegelthe symptoms she suffered: “12 hours after getting vaccinated, I suddenly had chills and fever, which at night reached 40.3”. The next day he took fever medication and went to work, but had to go home at noon.
A year of spraying against the coronavirus and other cases of “pandemic theater”
Strictly speaking, reactions to the vaccine are not side effects because they were already described and were to be expected. “In general, they are the same as those reported in clinical trials and are also similar to those observed in the other vaccines approved in Europe, BioNTech / Pfizer and Moderna,” says Carlos A. Guzmán, head of the Department of Vaccination and Applied Microbiology of the Helmholtz Center for Infection Research.
With the only difference, he points out, that “a slightly higher percentage” of those vaccinated with AstraZeneca develop a fever. The immunologist Watzl points out another small difference: while reactions to the Anglo-Swedish vaccine occur mainly after the first dose, in the case of the other two they have been described more after the second.
“It’s a shame,” says Zeeb, that people are left with some headlines and not better informed about what is happening in other countries, such as the UK, “where the AstraZeneca vaccine is being used massively without problems”, or not listening to the WHO, which recommends immunization “for all ages in adults.” Both he and Guzmán are optimistic: they believe that as soon as more data is published and communicated correctly, the reluctance of the Germans will disappear.